spinal muscular atrophy

News

Biogen buys CNS delivery specialist Alcyone Therapeutics

Biogen buys Alcyone, bringing a partnered technology for delivery of antisense drugs into the central nervous system in-house.

News

Biogen races into phase 3 with Spinraza follow-up

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.

News

SMA treatment with Evrysdi 'could start prenatally'

Should treatment of neurodegenerative disorder SMA with Roche's Evrysdi start even before birth? One case study suggests so.

News

US/EU regulators start review of Biogen's high-dose Spinraza

Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews - but can it help return the drug to growth?

News

New data could widen use of Novartis' SMA therapy Zolgensma

Phase 3 results with an intrathecal version of Novartis spinal muscular atrophy (SMA) gene therapy could make older children eligible for treatment.

News

Scholar Rock preps filings after SMA antibody clears trial

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory fi

Biogen buys CNS delivery specialist Alcyone Therapeutics

Biogen races into phase 3 with Spinraza follow-up

SMA treatment with Evrysdi 'could start prenatally'

US/EU regulators start review of Biogen's high-dose Spinraza

New data could widen use of Novartis' SMA therapy Zolgensma

Scholar Rock preps filings after SMA antibody clears trial

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

spinal muscular atrophy

Editor's Picks